Stephen Henry
CEO Managing Director @Kode Agalimmune
Signup · Get unlimited contacts
WORK HISTORY
CEO Managing Director @Kode Agalimmune
Kode Agalimmune Limited (KAL) is developing the AGI-134 construct to treat solid tumours.
EDUCATION
University of Gothenburg
PhD
University of Auckland
PhD
Auckland University of Technology
Diploma in Medical Laboratory Science - NZCS paramedical
University of Auckland
DSc (Doctor of Science)
SKILLS
ABOUT STEPHEN HENRY
Kode Biotech Group (KBG), under my leadership as Founder CEO for over 29 years, has pioneered transformative surface modification technology with broad applications in therapeutics, diagnostics, and consumer products. KBG\'s mission is to license Kode™ Technology as a foundational component for next-generation innovations. With multiple products generating revenue and a growing global research network, we continue to empower advancements in healthcare and beyond. My role includes overseeing R&D, fostering strategic partnerships, spinning out new SPV\'s, and enabling product development that aligns with our vision for accessible and versatile biotechnology solutions. By leveraging decades of extensive expertise in biotechnology, entrepreneurship, and licensing, I aim to position Kode Biotech as a catalyst for impactful industry breakthroughs.The Kode Biotech Group of companies (role as CEO/Director) include: Kode Biotech Ltd (Kode Technology licensing) Kode Agalimmune Ltd (AGI-134 - immunoeducer oncology therapeutic) KodeRx (K5K - immunoeducer oncology therapeutic) Equitable Oncology Ltd (charitable equitable oncology company) Kode Biotech Materials Ltd (scale Kode construct supply) GlycoNZ Ltd (R&D glycoconjugate supply - with Merck-MilliporeSigma as the USA distributor)Spin-out (controlled) Kode Group subsidiaries include: Kode Veterinary Sciences Ltd (Veterinary oncology)- role as Scientific Adviser to the Board
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.